According to Data Bridge Market Research new Market report “Europe Drug Delivery Market, By Route of Administration (Oral (Solid, Liquid, Semi-Solid), Injectable, Topical (Formulations, Transdermal Devices), Pulmonary (MDI, DPI, Nebulizers), Nasal, Ocular, Implantable, Transmucosal), By End-User (Hospitals, Clinics, Home Healthcare, Community Centers, Others), By Distribution Channel (Direct Tenders, Hospital Pharmacies, Pharmacy Stores, Online Pharmacies), By Country (Germany, France, U.K., Spain, Italy, Russia, Netherlands, Switzerland, Turkey, Belgium, Rest of Europe) – Trends and Forecast to 2024”, is projected to reach USD 536.1 billion by 2024, at a CAGR of 7.3% during the forecast period from 2017 to 2024. The new market report contains data for historic years 2014 & 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Report Access: https://www.databridgemarketresearch.com/reports/europe-drug-delivery-devices-market-trends-and-forecast-to-2024/
Increase in demand for biologics provides opportunities for the drug and the delivery devices manufacturers. Increasing number of regulatory approvals by the European Medicine Agency (EMA) have facilitated companies to introduce biologics used for various treatment purposes. According to the European Medicine Agency, in 2014, the highest number of orphan drugs—17 out 82 recommended drugs—received market authorization approvals in Europe. These orphan drugs are used for the treatment of rare diseases. In 2014, the EMA recommended the marketing authorization for eight new medicines, including Lynparza, Imbruvica, Gazyvaro, and Cyramza. These medicines are used for the treatment of a rare kind of cancer. According to ICON, the EMA approved 40 new medicines in 2014. The EMA increased its budget by 7% for reviewing the performing applications of initial marketing authorization, in 2015.
Europe Drug Delivery Market - Market Segmentation:
The Europe Drug Delivery market is segmented on the basis of route of administration, end-user, distribution channel, and geography.
On the basis of route of administration the Europe drug delivery market is segmented into oral, injectable, topical, pulmonary, nasal, ocular, implantable and transmucosal. Oral drug is further segmented based on form into solid drug, semi-solid drug and liquid drug. The solid drugs include and are categorized as tablets, capsules, powders and pills. The semi-solid drugs are further segmented into gels, emulsions and elixirs. The liquid drugs are further classified into solutions and syrups.
Based on end users the Europe drug delivery market is segmented into hospitals, over the counter, ambulatory surgery centers/clinics, home care settings, diagnostic centers, and others.
On the basis of distribution channel the market is segmented into Direct Tenders, Hospital Pharmacies, Pharmacy Stores, and Online Pharmacies.
Europe Drug Delivery Market - Geographical Segmentation
Based on geography the Europe Drug Delivery market is segmented into 11 countries, Germany, France, U.K., Spain, Italy, Russia, Netherlands, Switzerland, Turkey, Belgium, and Rest of Europe.
Europe Drug Delivery Market - Competitive Landscape:
The Europe drug delivery market is highly fragmented with various companies operating in local regions. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. Some of the examples for these strategies are In November 2016, In November, Pfizer Inc. announced that the European Commission (EC) has approved IBRANCE (palbociclib) for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer. The report includes company share data for different countries including Europe, Germany, France, U.K. and Rest of Europe.
Some of the major players operating in the Europe Drug Delivery Market are Bayer AG, Johnson & Johnson, Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc. , Merck & Co., Sanofi, Antares Pharma, 3M, Becton Dickinson and Company, Biolase, Inc., Cima Labs, Inc., West Pharmaceuticals, Antares Pharma, Alkermes, Foamis, Ypsomed, Skyepharma AG, Valeant Pharmaceuticals, DSM Biomedical and Catalent, Inc. among others.
Browse Related Reports:
Global Drug Delivery Devices Market, By Product Type (Oral (Solid, Liquid,Semi-Solid), Injectable (Devices (Conventional, Self-Injectable), Formulations), Topical (Transdermal Devices (Patches, Gels), Formulations), Pulmonary (MDI, DPI, Nebulizers), Nasal, Ocular, Implantable, Transmucosal), By End-User (Hospitals, Clinics, Home Healthcare, Community Healthcare, Others), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Direct Tenders, Online Pharmacy), By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa, Rest of the World) – Trends and Forecast to 2022
https://www.databridgemarketresearch.com/reports/global-drug-delivery-devices-market
Global Topical Drug Delivery Market, By Product Type (Topical Drug Delivery Formulations (Solid, Liquid, Semi Solid), Transdermal Drug Delivery Devices (Transdermal Patches, Transdermal Gels)), By End-User (Hospitals, Clinics, Home Healthcare, Diagnostic Centers, Others), By Distribution Channel (Direct Tenders, Retail), By Geography (North America, Europe, Asia-Pacific, Latin America, Rest of the World) – Trends and Forecast to 2024
Contact:
4th Floor, Mega Center,
Magarpatta City, Pune – 411028
Tel: +1-888-387-2818
Email: Sales@databridgemarketresearch.com
Visit Data Bridge Blog@ https://www.databridgemarketresearch.com/blog/
